SEATTLE, Feb. 11 /PRNewswire-FirstCall/ --Dendreon Corporation management will host a conference call on Monday, February 22, 2010 at 4:30 p.m. ET to review fourth quarter and full year 2009 financial results. Access to the discussion may be obtained as follows:
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
Dendreon Corporation
